GlassScriptPhysician profile
Srinivas Halthore
NPI 1730119413
$4,782.10
in general payments reported to CMS, 2019-2025
33 companies · $23.30 in 2025
The $23.30 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2021: $219 · 2022: $1,008 · 2023: $1,801 · 2024: $1,360 · 2025: $23.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,020.85 | 2021-2024 | Fintepla, Briviact |
| Livanova USA, INC. | $625.64 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $404.74 | 2022-2024 | Valtoco |
| Sarepta Therapeutics, INC. | $383.17 | 2022-2024 | Elevidys |
| Acadia Pharmaceuticals INC | $303.89 | 2023-2024 | Daybue |
| Jazz Pharmaceuticals INC. | $293.91 | 2019-2024 | Epidiolex, Xywav |
| Ptc Therapeutics, INC. | $252.90 | 2019-2024 | Emflaza |
| Biogen, INC. | $209.98 | 2021-2024 | Spinraza |
| Genentech USA, INC. | $160.16 | 2022-2024 | Evrysdi |
| Ns Pharma, INC. | $152.25 | 2023-2024 | Viltepso |
| Ipsen Biopharmaceuticals, INC | $136.75 | 2019-2024 | Dysport |
| Emd Serono, INC. | $106.60 | 2022-2023 | Mavenclad |
| Horizon Therapeutics Plc | $94.76 | 2022 | |
| Alexion Pharmaceuticals, INC. | $74.53 | 2022-2023 | Koselugo |
| Ironshore Pharmaceuticals INC. | $69.65 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $68.78 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $52.14 | 2019 | |
| Biomarin Pharmaceutical INC. | $44.21 | 2019-2024 | Brineura |
| Sk Life Science, INC. | $36.53 | 2024 | |
| Merz Pharmaceuticals, LLC | $34.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $32.07 | 2023 | Lyvispah |
| Catalyst Pharmaceuticals, INC. | $31.08 | 2024 | |
| Eisai INC. | $28.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.43 | 2024 | |
| Biocodex, INC. | $23.30 | 2025 | |
| Sumitomo Pharma America, INC. | $21.37 | 2023 | Aptiom |
| Cranial Technologies, INC | $19.65 | 2024 | Doc Band |
| Greenwich Biosciences, INC. | $15.43 | 2019 | |
| Saol Therapeutics INC. | $15.26 | 2019 | |
| Aquestive Therapeutics, INC. | $13.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.83 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.78 | 2021 | |
| Travere Therapeutics, INC. | $2.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Halthore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.